These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. NLR, MLR, and PLR are adverse prognostic variables for sleeve lobectomy within non-small cell lung cancer. Han R; Zhang F; Hong Q; Visar D; Zhan C; Zhao C; Wang F; Zhang S; Li F; Li J; Mu J Thorac Cancer; 2024 Aug; 15(24):1792-1804. PubMed ID: 39034535 [TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390 [TBL] [Abstract][Full Text] [Related]
5. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study. Lan H; Zhou L; Chi D; Zhou Q; Tang X; Zhu D; Yue J; Liu B Oncotarget; 2017 May; 8(21):35301-35310. PubMed ID: 27845912 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Zhang H; Xia H; Zhang L; Zhang B; Yue D; Wang C Am J Surg; 2015 Sep; 210(3):526-35. PubMed ID: 26105800 [TBL] [Abstract][Full Text] [Related]
7. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323 [TBL] [Abstract][Full Text] [Related]
8. Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients with Non-Small-Cell Lung Cancer. Guo M; Sun T; Zhao Z; Ming L Ann Thorac Cardiovasc Surg; 2021 Apr; 27(2):84-90. PubMed ID: 33162436 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of a novel scoring system using inflammatory response biomarkers in non-small cell lung cancer: A retrospective study. Wang Y; Hu X; Xu W; Wang H; Huang Y; Che G Thorac Cancer; 2019 Jun; 10(6):1402-1411. PubMed ID: 31104359 [TBL] [Abstract][Full Text] [Related]
10. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy. Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745 [TBL] [Abstract][Full Text] [Related]
11. Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Zhang J; Huang SH; Li H; Li Y; Chen XL; Zhang WQ; Chen HG; Gu LJ Med Oncol; 2013 Mar; 30(1):352. PubMed ID: 23275140 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Kim SH; Lee HW; Go SI; Lee SI; Lee GW Oncotarget; 2016 Jun; 7(24):36198-36206. PubMed ID: 27105529 [TBL] [Abstract][Full Text] [Related]
13. Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection. Jeong E; Hyun SH; Moon SH; Cho YS; Kim BT; Lee KH Medicine (Baltimore); 2017 Feb; 96(5):e5935. PubMed ID: 28151879 [TBL] [Abstract][Full Text] [Related]
14. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy. Yılmaz U; Ozdemir O; Batum O; Ermin S Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study. Takada K; Takamori S; Matsubara T; Haratake N; Akamine T; Kinoshita F; Ono Y; Wakasu S; Tanaka K; Oku Y; Oba T; Osoegawa A; Tagawa T; Takenoyama M; Shimokawa M; Oda Y; Mori M PLoS One; 2020; 15(11):e0241580. PubMed ID: 33137158 [TBL] [Abstract][Full Text] [Related]
16. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer. Shao N; Cai Q Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392 [TBL] [Abstract][Full Text] [Related]
17. Platelet-lymphocyte ratio is an independent prognostic factor in patients with ALK-positive non-small-cell lung cancer. Han Y; Wang J; Hong L; Sun L; Zhuang H; Sun B; Wang H; Zhang X; Ren X Future Oncol; 2017 Jan; 13(1):51-61. PubMed ID: 27523323 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer. Zhang T; Jiang Y; Qu X; Shen H; Liu Q; Du J PLoS One; 2014; 9(10):e111494. PubMed ID: 25360716 [TBL] [Abstract][Full Text] [Related]
19. Gamma-Glutamyl Transpeptidase to Platelet Ratio Is a Novel and Independent Prognostic Marker for Resectable Lung Cancer: A Propensity Score Matching Study. Zhao L; Li S; Ju J; Zhou H; Wang H; Che G Ann Thorac Cardiovasc Surg; 2021 Jun; 27(3):151-163. PubMed ID: 33536389 [TBL] [Abstract][Full Text] [Related]